Roche released operational and pricing details for its Axelios 1 sequencing platform at AGBT, claiming the system can deliver a standard 30X human genome for $150 in duplex mode and announcing a $750,000 list price for the instrument. Company representatives presented data on cancer and multi‑omics applications and signaled a formal launch this summer with pre‑orders opening after the conference. Roche framed Axelios as a sequencing‑by‑expansion nanopore platform positioned to compete on throughput and cost with other new entrants; the company cautioned that real‑world cost and performance will depend on yield and customer workflows. Axelios demonstrations included rapid human genome runs and applications in methylation and RNA sequencing. Laboratories and clinical groups will scrutinize per‑run yield, consumable pricing, and integration with existing bioinformatics pipelines before moving from interest to purchase decisions.